Pharmaceutical

CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoFH): Likelihood of Approval

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Homozygous Familial Hypercholesterolemia (HoFH).

Jul 6, 2024 - 04:00
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Homozygous Familial Hypercholesterolemia (HoFH).
Read the original article

Tags:

Previous Article

CTX-310 by CRISPR Therapeutics for Heterozygous familial hypercholesterolemia (h...

Next Article

CTX-310 by CRISPR Therapeutics for Hypertriglyceridemia: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: White House drug shortages task force MIA with lawmakers while Congress works on fixes

STAT+: White House drug shortages task force MIA with l...

Aug 11, 2023

FDA fast tracks Mendus’s acute myeloid leukaemia vaccine vividencel

FDA fast tracks Mendus’s acute myeloid leukaemia vaccin...

Sep 9, 2023

Genmab acquires biotechnology company ProfoundBio in $1.8bn deal

Genmab acquires biotechnology company ProfoundBio in $1...

May 23, 2024